CU23923B1 - Polipéptidos derivados de la il-2 con actividad agonista - Google Patents

Polipéptidos derivados de la il-2 con actividad agonista

Info

Publication number
CU23923B1
CU23923B1 CU2010000216A CU20100216A CU23923B1 CU 23923 B1 CU23923 B1 CU 23923B1 CU 2010000216 A CU2010000216 A CU 2010000216A CU 20100216 A CU20100216 A CU 20100216A CU 23923 B1 CU23923 B1 CU 23923B1
Authority
CU
Cuba
Prior art keywords
present
polypeptides
relates
disclosed
cancer
Prior art date
Application number
CU2010000216A
Other languages
English (en)
Other versions
CU20100216A7 (es
Inventor
Monzón Kalet León
Portilla Tania Carmenate
Rodríguez Saumel Pérez
Escalona Neris Michel Enamorado
Dávila Agustín Bienvenido Lage
Original Assignee
Ct De Inmunología Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45350376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU23923(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ct De Inmunología Molecular filed Critical Ct De Inmunología Molecular
Priority to CU2010000216A priority Critical patent/CU23923B1/es
Priority to CA2814814A priority patent/CA2814814C/en
Priority to HK13109794.4A priority patent/HK1182403B/xx
Priority to ES11797102.8T priority patent/ES2543915T3/es
Priority to CN201180054156.2A priority patent/CN103201284B/zh
Priority to MX2013005250A priority patent/MX346222B/es
Priority to EA201390681A priority patent/EA026022B1/ru
Priority to JP2013538062A priority patent/JP5761831B2/ja
Priority to MYPI2013700752A priority patent/MY171356A/en
Priority to PCT/CU2011/000007 priority patent/WO2012062228A2/es
Priority to BR112013010127-0A priority patent/BR112013010127B1/pt
Priority to PE2013001054A priority patent/PE20140382A1/es
Priority to KR1020137012452A priority patent/KR101559330B1/ko
Priority to EP11797102.8A priority patent/EP2639241B1/en
Priority to AU2011328688A priority patent/AU2011328688B2/en
Priority to US13/885,021 priority patent/US9206243B2/en
Priority to UAA201307450A priority patent/UA106318C2/ru
Priority to TW100141299A priority patent/TWI488864B/zh
Priority to PH1/2013/500937A priority patent/PH12013500937A1/en
Priority to ARP110104234A priority patent/AR083858A1/es
Publication of CU20100216A7 publication Critical patent/CU20100216A7/es
Priority to CO13103448A priority patent/CO6700862A2/es
Priority to CL2013001107A priority patent/CL2013001107A1/es
Priority to IL226221A priority patent/IL226221B/en
Publication of CU23923B1 publication Critical patent/CU23923B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a polipéptidos que comparten secuencia primaria con la IL-2 humana, excepto porque varios aminoácidos han sido mutados. Las mutaciones introducidas reducen sustancialmente la capacidad de estos polipéptidos para estimular in vitro e in vivo a las células T reguladoras (T CD4+CD5+FoxP3+) y le confieren una mayor eficacia en la terapia de tumores trasplantables murinos. La presente invención incluye además las aplicaciones terapéuticas de estas variantes mutadas, solas o en combinación con vacunas, para la terapia de enfermedades como el cáncer o infecciones donde la actividad de las células T reguladoras (Tregs) es relevante. La presente invención también se relaciona con plopéptidos específicos cuya secuencia de aminoácidos es divulgada en la presente invención. En otro aspecto la presente invención se relaciona con las composiciones farmacéuticas que comprenden como principio activo los polipéptidos divulgados. Por último, la presente invención se relaciona con el uso terapéutico de los polipéptidos y composiciones farmacéuticas divulgados dado su efecto modulador del sistema inmune sobre patologías como cáncer y enfermedades infecciosas crónicas.
CU2010000216A 2010-11-12 2010-11-12 Polipéptidos derivados de la il-2 con actividad agonista CU23923B1 (es)

Priority Applications (23)

Application Number Priority Date Filing Date Title
CU2010000216A CU23923B1 (es) 2010-11-12 2010-11-12 Polipéptidos derivados de la il-2 con actividad agonista
UAA201307450A UA106318C2 (ru) 2010-11-12 2011-11-10 Производный полипептид il-2 с агонистической активностью для лечения рака и хронических инфекций
BR112013010127-0A BR112013010127B1 (pt) 2010-11-12 2011-11-10 Polipeptídeo agonista da interleucina 2, proteína de fusão, composição farmacêutica útil na terapia do câncer e enfermidades infecciosas crônicas, e, uso do polipeptídeo
KR1020137012452A KR101559330B1 (ko) 2010-11-12 2011-11-10 암 및 만성 감염 치료를 위한, 효능제 활성을 갖는 인터루킨 2로부터 유도된 폴리펩티드
ES11797102.8T ES2543915T3 (es) 2010-11-12 2011-11-10 Polipéptidos derivados de la IL-2 con actividad agonista para la terapia del cáncer e infecciones crónicas
CN201180054156.2A CN103201284B (zh) 2010-11-12 2011-11-10 用于癌症和慢性感染的治疗的具有激动剂活性的衍生自il-2的多肽
MX2013005250A MX346222B (es) 2010-11-12 2011-11-10 Polipeptidos derivados de la il-2 con actividad agonista para la terapia del cancer e infecciones cronicas.
EA201390681A EA026022B1 (ru) 2010-11-12 2011-11-10 Производные полипептиды il-2 с агонистической активностью для лечения рака
JP2013538062A JP5761831B2 (ja) 2010-11-12 2011-11-10 癌及び慢性感染の治療のための作動薬活性を有するｉｌ−２由来のポリペプチド
MYPI2013700752A MY171356A (en) 2010-11-12 2011-11-10 Polypeptides derived from il-2 having agonist activity for the therapy of cancer and chronic infections
PCT/CU2011/000007 WO2012062228A2 (es) 2010-11-12 2011-11-10 Polipéptidos derivados de la il-2 con actividad agonista para la terapia del cáncer e infecciones crónicas.
CA2814814A CA2814814C (en) 2010-11-12 2011-11-10 Polypeptides derived from il-2 having agonist activity, for the therapy of cancer and chronic infections
PE2013001054A PE20140382A1 (es) 2010-11-12 2011-11-10 Polipeptidos derivados de la il-2 con actividad agonista para la terapia del cancer e infecciones cronicas
HK13109794.4A HK1182403B (en) 2010-11-12 2011-11-10 Polypeptides derived from il-2 having agonist activity, for the therapy of cancer and chronic infections
EP11797102.8A EP2639241B1 (en) 2010-11-12 2011-11-10 Polypeptides derived from il-2 having agonist activity, for the therapy of cancer and chronic infections
AU2011328688A AU2011328688B2 (en) 2010-11-12 2011-11-10 Polypeptides derived from IL-2 having agonist activity, for the therapy of cancer and chronic infections
US13/885,021 US9206243B2 (en) 2010-11-12 2011-11-10 IL-2 derivative polypeptides
ARP110104234A AR083858A1 (es) 2010-11-12 2011-11-11 Polipeptidos derivados de la il-2 con actividad agonista para la terapia del cancer e infecciones cronicas
TW100141299A TWI488864B (zh) 2010-11-12 2011-11-11 用於治療癌症及慢性感染之具有促效劑活性之介白素－２（ｉｌ－２）衍生物多肽
PH1/2013/500937A PH12013500937A1 (en) 2010-11-12 2011-11-11 Polypeptides derived from il-2 having agonist activity, for the therapy of cancer and chronic infections
CO13103448A CO6700862A2 (es) 2010-11-12 2013-04-23 Polipéptidos derivados de la il-2 con actividad agonista para la terapia del cáncer e infecciones crónicas.
CL2013001107A CL2013001107A1 (es) 2010-11-12 2013-04-23 Polipeptido derivado de la il-2 con actividad agonista; proteina de fusion que lo comprende; composicion farmaceutica que lo comprende; y su uso para tratar cancer y enfermedades infecciosas cronicas.
IL226221A IL226221B (en) 2010-11-12 2013-05-07 Polypeptides derived from 2-il have agonistic activity, for the cure of cancer and chronic inflammations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2010000216A CU23923B1 (es) 2010-11-12 2010-11-12 Polipéptidos derivados de la il-2 con actividad agonista

Publications (2)

Publication Number Publication Date
CU20100216A7 CU20100216A7 (es) 2012-06-21
CU23923B1 true CU23923B1 (es) 2013-07-31

Family

ID=45350376

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2010000216A CU23923B1 (es) 2010-11-12 2010-11-12 Polipéptidos derivados de la il-2 con actividad agonista

Country Status (22)

Country Link
US (1) US9206243B2 (es)
EP (1) EP2639241B1 (es)
JP (1) JP5761831B2 (es)
KR (1) KR101559330B1 (es)
CN (1) CN103201284B (es)
AR (1) AR083858A1 (es)
AU (1) AU2011328688B2 (es)
BR (1) BR112013010127B1 (es)
CA (1) CA2814814C (es)
CL (1) CL2013001107A1 (es)
CO (1) CO6700862A2 (es)
CU (1) CU23923B1 (es)
EA (1) EA026022B1 (es)
ES (1) ES2543915T3 (es)
IL (1) IL226221B (es)
MX (1) MX346222B (es)
MY (1) MY171356A (es)
PE (1) PE20140382A1 (es)
PH (1) PH12013500937A1 (es)
TW (1) TWI488864B (es)
UA (1) UA106318C2 (es)
WO (1) WO2012062228A2 (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2860170C (en) 2010-12-22 2022-06-14 The Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
CN105440123B (zh) 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
SI3102595T1 (sl) 2014-02-06 2019-02-28 F. Hoffmann-La Roche Ag Fuzijske beljakovine z interlevkinom-2 in njihova uporaba
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US10150802B2 (en) 2014-04-24 2018-12-11 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
PL3134127T3 (pl) * 2014-04-25 2020-07-27 Rinat Neuroscience Corp. Koniugaty przeciwciało-lek o dużym ładunku leku
PL3482766T3 (pl) 2014-08-11 2020-11-16 Delinia, Inc. Modyfikowane warianty il-2, które selektywnie aktywują limfocyty t regulatorowe do leczenia chorób autoimmunologicznych
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
WO2017220989A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
EA201991142A1 (ru) 2016-11-08 2019-10-31 Варианты il-2 для лечения аутоиммунных заболеваний
CA3043597A1 (en) * 2016-11-10 2018-05-17 Nektar Therapeutics Immunotherapeutic tumor treatment method
CU24483B1 (es) 2016-11-15 2020-04-02 Ct Inmunologia Molecular Método para incrementar los niveles de secreción de la interleucina-2
CA3056630A1 (en) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Targeted immunotolerance
JP2020521452A (ja) 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
PE20251254A1 (es) 2017-05-24 2025-05-06 Novartis Ag Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer
EP3641814A4 (en) 2017-06-19 2021-06-23 Medicenna Therapeutics Inc. USES AND METHODS FOR IL-2 SUPERAGONISTS AND AGONISTS AND FUSIONS THEREOF
EP3713592A4 (en) 2017-11-21 2022-01-12 The Board of Trustees of the Leland Stanford Junior University INTERLEUKIN-2 PARTIAL AGONISTS
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
MA51291A (fr) 2017-12-19 2020-10-28 Xencor Inc Protéines de fusion il-2 fc modifiées
EP3762406A2 (en) * 2018-03-09 2021-01-13 Askgene Pharma, Inc. Cytokine prodrugs
CU24554B1 (es) * 2018-05-07 2021-11-04 Ct Inmunologia Molecular Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1
SG11202011308VA (en) 2018-05-14 2020-12-30 Werewolf Therapeutics Inc Activatable cytokine polypeptides and methods of use thereof
JP7460609B2 (ja) 2018-05-14 2024-04-02 ウェアウルフ セラピューティクス， インコーポレイテッド 活性化可能なインターロイキン－２ポリペプチド及びその使用方法
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
US12459980B2 (en) 2018-07-25 2025-11-04 AskGene Pharma, Inc. IL-21 prodrugs and methods of use thereof
HUE068059T2 (hu) 2018-09-17 2024-12-28 Gi Innovation Inc Il-2 fehérjét és CD80 fehérjét tartalmazó fúziós fehérje és annak felhasználása
US20220002370A1 (en) 2018-09-27 2022-01-06 Xilio Development, Inc. Masked cytokine polypeptides
TWI840433B (zh) * 2018-10-29 2024-05-01 大陸商北京強新生物科技有限公司 新穎合理設計的蛋白質組合物
KR20210107714A (ko) 2018-12-21 2021-09-01 지앙수 헨그루이 메디슨 컴퍼니 리미티드 인간 인터류킨-2 변이체 또는 이의 유도체
CU24712B1 (es) * 2019-03-15 2024-07-10 Centre Hospitalier Univ Vaudois Método para la expansión y diferenciación de linfocitos t y células nk en terapias de transferencia adoptiva
EP3969035A4 (en) 2019-05-14 2023-06-21 Werewolf Therapeutics, Inc. SEPARATION UNITS AND METHODS AND THEIR USE
CA3141327A1 (en) 2019-05-20 2020-11-26 Pandion Operations, Inc. Madcam targeted immunotolerance
WO2020247598A1 (en) * 2019-06-05 2020-12-10 Emory University Photolysis to unlock caged protein therapeutics
AU2020291012B2 (en) 2019-06-12 2025-09-25 AskGene Pharma, Inc. Novel IL-15 prodrugs and methods of use thereof
CN120795117A (zh) * 2019-06-14 2025-10-17 科优基因公司 用于癌症治疗的新型白介素-2变体
CA3153785A1 (en) 2019-09-28 2021-04-01 AskGene Pharma, Inc. Cytokine prodrugs and dual-prodrugs
MX2022005666A (es) 2019-11-14 2022-10-07 Werewolf Therapeutics Inc Polipeptidos de citocina activables y metodos de uso de los mismos.
WO2021127495A1 (en) 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
JP2023514010A (ja) 2020-01-10 2023-04-05 ブライト ピーク セラピューティクス エージー 修飾ｉｌ－２ポリペプチドおよびその使用
CN115362168A (zh) 2020-01-14 2022-11-18 辛德凯因股份有限公司 偏向化il2突变蛋白方法和组合物
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
TW202203973A (zh) 2020-04-22 2022-02-01 美商默沙東藥廠 對介白素-2受體βγc二聚體具偏性且結合至非肽、水溶性聚合物之人類介白素-2結合物
JPWO2022059794A1 (es) * 2020-09-18 2022-03-24
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
MX2023004598A (es) 2020-10-23 2023-06-29 Asher Biotherapeutics Inc Fusiones con moléculas de unión al antígeno cd8 para modular la función de las células inmunitarias.
CA3201446A1 (en) 2020-11-13 2022-05-19 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising human interleukin 2 variant or derivative thereof and use thereof
TW202235431A (zh) 2020-11-25 2022-09-16 美商艾希利歐發展股份有限公司 腫瘤特異性可裂解連接子
JP2024529297A (ja) 2021-07-09 2024-08-06 ブライト ピーク セラピューティクス エージー Ｉｌ－２を有するチェックポイント阻害剤のコンジュゲート及びその使用
US20230201364A1 (en) 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Antibody conjugates and manufacture thereof
CA3222358A1 (en) 2021-07-09 2023-01-12 Vijaya Raghavan PATTABIRAMAN Checkpoint inhibitors conjugated to il-2, and uses thereof
US20230201365A1 (en) 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Modified cd20 antibodies and uses thereof
JP7618848B2 (ja) 2021-07-30 2025-01-21 ドラコターピン バイオメディスン エルエルシー ヒトインターロイキン－２変異体およびその使用
CU24763B1 (es) 2021-12-21 2025-07-09 Ct Inmunologia Molecular Proteínas de fusión compuestas por un anticuerpo y una muteína agonista de interleucina 2
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
US20240132563A1 (en) 2022-02-23 2024-04-25 Bright Peak Therapeutics Ag Bifunctional cytokine compositions
US20250215452A1 (en) 2022-03-25 2025-07-03 Universität Zürich Adenoviral Mediated Targeting of Activated Immune Cells
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
CN115850436A (zh) * 2022-10-14 2023-03-28 海徕科(北京)生物技术有限公司 白介素2突变体及其应用
WO2024119193A2 (en) 2022-12-02 2024-06-06 AskGene Pharma, Inc. Mutant il-2 polypeptides and il-2 prodrugs
US20240376170A1 (en) 2023-01-11 2024-11-14 Bright Peak Therapeutics Ag Conditionally activated proteins and methods of use
WO2024150174A1 (en) 2023-01-11 2024-07-18 Bright Peak Therapeutics Ag Conditionally activated immunocytokines and methods of use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853332A (en) 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
FR2624741B1 (fr) * 1987-12-21 1991-06-28 Pasteur Institut Compositions a base d'une combinaison de liposomes et de lymphokine presentant des proprietes immunostimulantes et leurs applications en medecine humaine et veterinaire
WO1990004412A1 (en) * 1988-10-27 1990-05-03 Regents Of The University Of Minnesota Liposome immunoadjuvants containing il-2
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
DZ2788A1 (fr) * 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US6955807B1 (en) * 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
EP2354791A1 (en) 2001-12-04 2011-08-10 Merck Patent GmbH Immunocytokines with modulated selectivity
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
CN1609227A (zh) * 2003-10-24 2005-04-27 中国科学院沈阳应用生态研究所 一种白介素－4突变基因il－4－13及其制备和应用
JP5022216B2 (ja) * 2004-06-04 2012-09-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 自己炎症性疾患を処置するためのｉｌ−１アンタゴニストを使用する方法
AU2007271398B2 (en) * 2006-07-06 2013-06-20 Merck Patent Gmbh Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses
WO2009061853A2 (en) * 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Mutant interleukin-2 (il-2) polypeptides
DE102008023820A1 (de) * 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
US20110274650A1 (en) * 2009-01-21 2011-11-10 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases

Also Published As

Publication number Publication date
CA2814814C (en) 2015-12-22
JP5761831B2 (ja) 2015-08-12
TWI488864B (zh) 2015-06-21
JP2014500868A (ja) 2014-01-16
US9206243B2 (en) 2015-12-08
BR112013010127A2 (pt) 2016-08-30
AR083858A1 (es) 2013-03-27
MY171356A (en) 2019-10-10
KR101559330B1 (ko) 2015-10-12
CL2013001107A1 (es) 2014-01-10
ES2543915T3 (es) 2015-08-25
WO2012062228A2 (es) 2012-05-18
MX2013005250A (es) 2013-08-29
EP2639241B1 (en) 2015-07-08
CN103201284B (zh) 2015-07-01
CO6700862A2 (es) 2013-06-28
CU20100216A7 (es) 2012-06-21
EA201390681A1 (ru) 2013-08-30
IL226221A0 (en) 2013-07-31
KR20130091346A (ko) 2013-08-16
US20140314709A1 (en) 2014-10-23
IL226221B (en) 2018-10-31
EA026022B1 (ru) 2017-02-28
AU2011328688B2 (en) 2015-05-14
TW201300409A (zh) 2013-01-01
CN103201284A (zh) 2013-07-10
AU2011328688A1 (en) 2013-05-02
EP2639241A2 (en) 2013-09-18
HK1182403A1 (en) 2013-11-29
PE20140382A1 (es) 2014-03-24
WO2012062228A3 (es) 2012-07-05
PH12013500937A1 (en) 2017-08-23
MX346222B (es) 2017-03-09
UA106318C2 (ru) 2014-08-11
BR112013010127B1 (pt) 2021-12-14
CA2814814A1 (en) 2012-05-18

Similar Documents

Publication Publication Date Title
CU23923B1 (es) Polipéptidos derivados de la il-2 con actividad agonista
CU23734A1 (es) Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
EA201101518A1 (ru) Фармацевтическая композиция для применения в медицинской и ветеринарной офтальмологии
IN2012DN06720A (es)
MD4577B1 (ro) Compoziţii masticabile de uz veterinar care conţin agent activ izoxazolinic şi utilizarea acestora în tratamentul sau prevenirea unei infestări sau infecţii parazitare
ECSP14012676A (es) Compuestos de carbamato y preparación y uso de los mismos
MY188139A (en) Sodium channel modulators for the treatment of pain
MX363007B (es) Uso de n-acetil-5-metoxi-triptamina o analogos de la misma para potenciar el mecanismo de implantacion del embrion, y composiciones y medios de cultivo relacionados.
BR112013008601A8 (pt) Formulações de emulsão de clevidipina contendo agentes antimicrobianos
EA201491479A1 (ru) Производные лупановых тритерпеноидов и их фармацевтическое применение
CL2012001836A1 (es) Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros.
BR112014011981B8 (pt) Formulações farmacêuticas sólidas orais, seus processos de preparação e usos
TR200900878A2 (tr) Tek bir dozaj formunda kombine edilen farmasötik formülasyonlar
CR20140475A (es) Agentes terapéuticos para administración subcutánea optimizados
UY35091A (es) Formulaciones de liberacion modificada para oprozomib
TR200900879A2 (tr) Aktif maddelerin tek bir dozaj formunda kombine edildiği farmasötik bileşimler
SMT201500048B (it) Composizione farmaceutica con attivita'antimicrobica e cicatrizzante per somministrazione esterna e procedimento per la preparazione della stessa
MX2015013115A (es) Nuevos regimenes de dosificacion de celgosivir para el tratamiento de dengue.
MX391191B (es) Composiciones de liberación extendida de onapristona y métodos.
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
TR200900880A2 (tr) Tek bir dozaj formunda kombine edilen farmasötik bileşimler.
TN2013000151A1 (en) Polypeptides derived from il-2 having agonist activity for the therapy of cancer and chronic infections
EA201491477A1 (ru) Фармацевтические составы, содержащие флупиртин
TR201714726A1 (tr) Antikolinerjik bir etken madde içeren farmasötik formülasyon.
TR201201022A2 (tr) Akciğer hastalıkları, karaciğer hastalıkları ve çeşitli enfeksiyonların semptomatik ve/veya terapötik tedavisinde kullanılan farmasötik bileşimler.

Legal Events

Date Code Title Description
FG Grant of patent